This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weigel, B. J. Articles by Blazar, B. R. Search for Related Content PubMed PubMed Citation Articles by Weigel, B. J. Articles by Blazar, B. R.

CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma¹

University of Minnesota Cancer Center, Department of Pediatrics, Division of Pediatric Hematology/Oncology and Bone Marrow Transplantation, Minneapolis, Minnesota 55455 [B. J. W., B. R. B.]; Department of Surgery, Mayo Clinic and Foundation, Rochester, Minnesota 55905 [D. A. R.]; Department of Veterans Affairs Medical Center and the Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242 [A. M. K.]; and Coley Pharmaceutical Group, Wellesley, Massachusetts 02481 [A. M. K.]

Purpose: CpG oligodeoxynucleotides (ODNs) are synthetic DNA sequences that mimic bacterial DNA and have potent immunostimulatory effects on dendritic cells (DCs), B cells, and natural killer cells. To evaluate CpG ODN antitumor effects against solid tumors, we used an orthotopic murine model of embryonal rhabdomyosarcoma.

Experimental Design: The systemic administration of CpG 2006 was tested beginning on day 9 or 19 when tumors were not yet palpable or palpable, respectively, and after surgical resection of the tumor. CpG was also administered in combination with the chemotherapeutic agents, cyclophosphamide (CY) and topotecan, or surgical resection.

Results: Systemic CpG prolonged survival when begun at day 9 but had no effect with a large tumor burden. CpG administered after surgical resection of tumor significantly improved survival of mice (P < 0.03). On day 9, CY plus CpG 2006 resulted in improved survival compared with CY alone (70% versus 41%, respectively). Survival was significantly improved when CpG 2006 was administered systemically with CY beginning on day 19 (15% versus 0% survival). The administration of CpG 2006 with topotecan significantly improved survival in mice with large tumors. Cell-depletion studies demonstrated that the antitumor effects of systemically administered CpG 2006 combined with CY were predominantly T cell dependent.

Conclusions: These data are the first to show that immune stimulatory agents such as CpGs may enhance the antitumor effects of chemotherapeutic agents and improve survival after surgical resection of a solid tumor.

This article has been cited by other articles:

				D. Klinman, H. Shirota, D. Tross, T. Sato, and S. Klaschik Synthetic oligonucleotides as modulators of inflammation J. Leukoc. Biol., October 1, 2008; 84(4): 958 - 964. [Abstract] [Full Text] [PDF]

				Z. Xiong, S. Gharagozlou, I. Vengco, W. Chen, and J. R. Ohlfest Effective CpG Immunotherapy of Breast Carcinoma Prevents but Fails to Eradicate Established Brain Metastasis Clin. Cancer Res., September 1, 2008; 14(17): 5484 - 5493. [Abstract] [Full Text] [PDF]

				C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh, G. Albert, M. Al-Adhami, D. Readett, A. M. Krieg, and C. G. Leichman Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung Cancer J. Clin. Oncol., August 20, 2008; 26(24): 3979 - 3986. [Abstract] [Full Text] [PDF]

				L. Zheng, N. Asprodites, A. H. Keene, P. Rodriguez, K. D. Brown, and E. Davila TLR9 engagement on CD4 T lymphocytes represses {gamma}-radiation-induced apoptosis through activation of checkpoint kinase response elements Blood, March 1, 2008; 111(5): 2704 - 2713. [Abstract] [Full Text] [PDF]

				F. G. Barr and W. H. Meyer Rhabdomyosarcoma: An Overview of Biology, Clinical Features, and the Current Children's Oncology Group Studies ASCO Educational Book, January 1, 2008; 2008(1): 465 - 470. [Abstract] [Full Text] [PDF]

				J. Li, W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself J. Immunol., August 15, 2007; 179(4): 2493 - 2500. [Abstract] [Full Text] [PDF]

				M. H.M.G.M. den Brok, R. P.M. Sutmuller, S. Nierkens, E. J. Bennink, L. W.J. Toonen, C. G. Figdor, T. J.M. Ruers, and G. J. Adema Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine. Cancer Res., July 15, 2006; 66(14): 7285 - 7292. [Abstract] [Full Text] [PDF]

				R. Kim, M. Emi, K. Tanabe, and K. Arihiro Tumor-Driven Evolution of Immunosuppressive Networks during Malignant Progression Cancer Res., June 1, 2006; 66(11): 5527 - 5536. [Abstract] [Full Text] [PDF]

				P. P. Breitfeld and W. H. Meyer Rhabdomyosarcoma: New Windows of Opportunity Oncologist, August 1, 2005; 10(7): 518 - 527. [Abstract] [Full Text] [PDF]

				G. Pratesi, G. Petrangolini, M. Tortoreto, A. Addis, S. Belluco, A. Rossini, S. Selleri, C. Rumio, S. Menard, and A. Balsari Therapeutic Synergism of Gemcitabine and CpG-Oligodeoxynucleotides in an Orthotopic Human Pancreatic Carcinoma Xenograft Cancer Res., July 15, 2005; 65(14): 6388 - 6393. [Abstract] [Full Text] [PDF]

				K. A. Mason, H. Ariga, R. Neal, D. Valdecanas, N. Hunter, A. M. Krieg, J. K. Whisnant, and L. Milas Targeting Toll-like Receptor 9 with CpG Oligodeoxynucleotides Enhances Tumor Response to Fractionated Radiotherapy Clin. Cancer Res., January 1, 2005; 11(1): 361 - 369. [Abstract] [Full Text] [PDF]

				L. Milas, K. A. Mason, H. Ariga, N. Hunter, R. Neal, D. Valdecanas, A. M. Krieg, and J. K. Whisnant CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation Cancer Res., August 1, 2004; 64(15): 5074 - 5077. [Abstract] [Full Text] [PDF]